Peripheral T Cell Lymphoma
Conditions
Brief summary
As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse after initial therapy for peripheral T-cell lymphomas which is being given for curative intent. Additionally, as more is known about the ability of dynamic monitoring of cfDNA in B-cell lymphomas to predict relapse, the investigators wish to explore the use of this technology in T-cell lymphomas.
Interventions
PROCEDURETumor biopsy
Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
PROCEDUREPeripheral blood draw
-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
PROCEDURELymphotrack TCR clonality assay
-Assay with high sensitivity that can be performed with peripheral blood
Sponsors
Invivoscribe, Inc.
National Cancer Institute (NCI)
T-Cell Leukemia Lymphoma Foundation
Washington University School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 18 years of age. * Histologically-confirmed peripheral T-cell lymphoma being treated with curative intent. Eligible histologies include, but are not limited to: peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphoma, ALK negative; and anaplastic large cell lymphoma, ALK positive. * Plan for treatment with frontline multi-agent anthracycline containing chemotherapy for curative intent (for example, CHOP, CHOEP, EPOCH). A frontline therapy program can include different sequential phases of treatment, including high-dose therapy and autologous stem cell transplantation. * Availability of pre-treatment test specimen from bone marrow, blood, lymph node, or alternate site to identify tumor-specific clonotype, or willingness to undergo biopsy if sufficient tissue is not available at time of enrollment (e.g. 15 slides from fixed formalin-fixed paraffin embedded tumor tissue \*Patients who have less than 15 slides of fixed formalin-fixed paraffin embedded tumor tissue may be considered for enrollment after discussion with the study principal investigator * Able to understand and willing to sign an IRB approved written informed consent document.
Exclusion criteria
* Receiving second line of therapy or greater. * Diagnosis of primary cutaneous T-cell lymphoma, extranodal NK-cell lymphoma, acute T-cell lymphoma/leukemia, hepatosplenic T-cell lymphoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of LymphoTrack TCR clonality assay of evaluating minimal residual disease as measured by progression-free survival (PFS) at the completion of 2 years | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate whether LymphoTrack TCR clonality assay can distinguish participants with peripheral T-cell lymphomas (PTCL) who are at risk of relapse | Through 2 years |
| Percentage of participants with a dominant tumor sequence identified from the pre-treatment test specimen | Baseline |
| Feasibility of LymphoTrack TCR clonality assay of evaluating minimal residual disease as measured by the ability of Lymphotrack to detect minimal residual disease in at least 60% of baseline samples | Baseline |
| Rate of decline of the tumor specific sequence or sequences predict duration of response | Through 2 years |
| Characterize the lead time from MRD positivity to subsequent clinical relapse | Through 2 years |
| Determine whether monitoring for the tumor-specific clone at minimal residual disease (MRD) level predicts response to treatment | Through 2 years |
Countries
United States
Outcome results
None listed